ReviewMolecular psychiatry2022
Mechanisms of action of fluvoxamine for COVID-19: a historical review.
Review in Molecular psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 5 syntheses or guidelines pooled it, 122 citations in OpenAlex.
- A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications.Scientific reports · 2024Pooled it
- Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023Pooled it
- Joint European policy on the COVID-19 risks for people with mental disorders: An umbrella review and evidence- and consensus-based recommendations for mental and public health.European psychiatry : the journal of the Association of European Psychiatrists · 2022Pooled it
- Antidepressants for COVID-19: A systematic review.Journal of affective disorders · 2022Pooled it
- The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial.BMC infectious diseases · 2023Trial
- Drug Repurposing as a Broad-Spectrum Strategy Against Coronaviruses: Frontiers in Mechanisms and Clinical Translation.Viruses · 2026Review
- Antiviral Activity of Essential Oil fromMolecules (Basel, Switzerland) · 2026Article
- SARS-CoV-2 in Infants: Clinical Patterns, Laboratory Findings, and Implications for Pediatric Care in Viral Outbreaks.Clinical medicine insights. Pediatrics · 2026Article
- The sigma-1 receptor agonist fluvoxamine alleviates endotoxin-induced acute lung injury in mice.Frontiers in pharmacology · 2026Article
- SSRI/SNRI and long COVID in children and adolescents with neuropsychiatric conditions: a cohort study from the RECOVER Initiative.Nature. Mental health · 2026Article
- A comprehensive mechanistic multicellular model of the human immune system spanning 11 diseases.Frontiers in immunology · 2026Article
- Immunomodulatory and anti-inflammatory effects of fluvoxamine during the intestinal phase of Trichinella spiralis infection in mice.Parasitology research · 2025Article
- An Overview of the Systematic Reviews About the Efficacy of Fluvoxamine on Depression.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Cilnidipine exerts antiviral effects in vitro and in vivo by inhibiting the internalization and fusion of influenza A virus.BMC medicine · 2025Article
- Fluvoxamine: First comprehensive insights into its molecular characteristics and inclusion complexation with β-cyclodextrin.Journal of pharmaceutical analysis · 2025Article
- Investigating the relationship between cycle threshold of SARS-CoV-2 RT-PCR, clinical features, and laboratory data in hospitalized COVID-19 patients in Semnan, Iran.Frontiers in cellular and infection microbiology · 2025Article
- Unfurling the Potential of Antiviral Agents Aimed for RNA Virus Ailment.Current drug targets · 2025Review
- Association between selective serotonin reuptake inhibitors and mortality following COVID-19 among patients with Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2024Article
- Ketamine and its two enantiomers in anesthesiology and psychiatry: A historical review and future directions.Journal of anesthesia and translational medicine · 2024Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) accelerates the discovery of prophylactic and therapeutic drugs for persons infected with the virus. Drug repurposing for the COVID-19 pandemic has received particular attention. Increasing clinical data suggest that antidepressant use in early-stage subjects with COVID-19 might be associated with a reduced risk of intubation or death. Among the antidepressants, fluvoxamine is the most attractive drug for mild to moderate subjects with COVID-19. In this article, we review the mechanisms of action (i.e., serotonin transporter, sigma-1 receptor, and acid sphingomyelinase) of fluvoxamine for COVID-19. Furthermore, we discuss a possible link between maternal COVID-19 infection and a risk for neuropsychiatric disorders (i.e., autism spectrum disorder and schizophrenia) in offspring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.